Interpretation for the mechanism of acquired resistance of EGFR blockade by using cell free DNA
| Project/Area Number |
26462030
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Nippon Medical School |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
小泉 岐博 日本医科大学, 医学部, 助教 (40328802)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
|
|---|
| Keywords | 大腸癌 / 抗EGFR抗体 / Liquid biopsy / Circulating DNA / Circulating tumor DNA / liquid biopsy / 循環DNA / circulating tumor DNA / circulating DNA / KRAS / 薬剤耐性 / cell free DNA / 2次耐性 |
|---|
| Outline of Final Research Achievements |
KRAS mutation is detected in circulating cell-free DNA of 10% of patients with KRAS wild colorectal cancer. EGFR blockade has no cyto-reductive effect in those patients. EGFR blockade has cyto-reductive effect in patients with both KRAS and BRAF wild in primary tumor and circulating cell free DNA. KRAS mutation is detected in circulating cell free DNA of 80% of patients who have got acquired resistance to EGFR blockade. Also, BRAF mutation is detected in circulating cell free DNA of 40% of patients who have got acquired resistance to EGFR blockade.
|
Report
(4 results)
Research Products
(12 results)
